0.10Open0.17Pre Close1 Volume178 Open Interest8.00Strike Price10.00Turnover107.53%IV10.94%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.1488Delta0.2496Gamma118.27Leverage Ratio-0.0308Theta-0.0001Rho-17.60Eff Leverage0.0020Vega
Emergent BioSolutions Stock Discussion
$Biomea Fusion (BMEA.US)$ Covalent III Trial regarding Type 2 Diabetes mellitus out tomorrow 8AM ET. SI 44.16%. COH $62.4M good for 6.2 months
$Sidus Space (SIDU.US)$ Satellite launch Friday. May continue until launch. Low float. 0 shares LTB.COH $4.8M good for 4.2 months
$Maison Solutions (MSS.US)$...
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Emergent BioSolutions (NYSE: EBS) has received a $50 million contract option from BARDA for its CYFENDUS® anthrax vaccine. The deliveries are scheduled between now and April 2025. This follows a previous $30 million contract modification for the same vaccine. CYFENDUS®, FDA-approved in July 2023, is a two-dose anthrax vacci...
Just
Emergent BioSolutions Receives $50 Million Contract Option From Barda to Procure Doses of Cyfendus® (Anthrax Vaccine Adsorbed, Adjuvanted
Emergent BioSolutions Inc - Cyfendus Vaccine Deliveries Expected to Complete by April 2025
$Synopsys (SNPS.US)$ $Futu Holdings Ltd (FUTU.US)$ $IonQ Inc (IONQ.US)$
No comment yet